Post Traumatic Stress Disorder (PTSD) Clinical Trial
Official title:
Mifepristone After Trauma to Enhance Resilience
he purpose of this study is to test whether a medication, called mifepristone (commonly known as the ³Morning-After-Pill²), can help to prevent emotional problems after someone has survived a traumatic experience. We are studying this medication for the treatment of Post-traumatic Stress disorder (PTSD.
PTSD is an emotional illness that can develop in people after they have experienced a
traumatic event. It involves symptoms such as poor sleep, nightmares about the trauma,
unwanted daytime memories of the trauma (flashbacks), jumpiness, and trouble looking forward
to things in the future. Once people develop PTSD, the symptoms tend to last a very long
time.
We are testing the idea that mifepristone, which blocks the effect of the hormones
progesterone and cortisol, will help treat PTSD. Progesterone is a hormone made in the
bodies of both men and women and its main role is in regulating the menstrual cycle and in
pregnancy. Cortisol is also a hormone made in the body of both men and women and helps the
body respond to stress. Cortisol also has a role in making emotional memories more intense
than other memories. We are testing whether blocking the effect of cortisol with
mifepristone as you recall your trauma may be able to decrease the intensity of your
traumatic memories. This medication will not completely block out your memories of the
traumatic experience but may decrease how much your thoughts are drawn back to the memory of
the traumatic event.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01545505 -
Identification of Markers of Post-Traumatic Stress Disorder (PTSD) Relapse
|
N/A | |
| Completed |
NCT02966873 -
Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)
|
Phase 2 | |
| Completed |
NCT04827056 -
Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study
|
Phase 1 | |
| Completed |
NCT04073862 -
The Norwegian Stepped-Care TF-CBT Study
|
N/A | |
| Recruiting |
NCT05254379 -
Transcranial Direct Current Stimulation Treatment for Warriors Experiencing Chronic Pain
|
N/A | |
| Terminated |
NCT02077972 -
Whole Body Hyperthermia & Combat-Related Posttraumatic Stress Disorder (PTSD)
|
N/A | |
| Completed |
NCT04086654 -
Psychometric Properties of the International Trauma Interview (ITI) for ICD-11 PTSD and CPTSD
|
N/A | |
| Completed |
NCT02723097 -
A Pilot Test of the Relaxation Response Resiliency Program (3RP) in Spanish Speaking World Trade Center Survivors With Post Traumatic Stress Disorder (PTSD)
|
N/A | |
| Completed |
NCT01629537 -
A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder
|
Phase 2 | |
| Withdrawn |
NCT00641511 -
Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)
|
Phase 2 | |
| Recruiting |
NCT04558437 -
COVID-Impact "Psychological IMPACT of Covid-19 on AP-HP Staff"
|
||
| Not yet recruiting |
NCT06162741 -
Type I Hybrid Effectiveness-Implementation Trial of Primary Care Brief Mindfulness Training for Veterans
|
N/A | |
| Completed |
NCT02764983 -
Occupational Therapy Driving Intervention for Returning Combat Veterans.
|
N/A | |
| Completed |
NCT02765672 -
Effectiveness of a Driving Intervention on Safe Community Mobility for Returning Combat Veterans
|
N/A | |
| Not yet recruiting |
NCT06335407 -
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
|
Phase 1 |